Toxicity Risks of Fuzi Marker Compound Revealed

Fuzi, a traditional medicine used for cardiovascular diseases and rheumatoid arthritis, contains a compound called 10-hydroxyl mesaconitine (10-OH MA). Researchers have identified 10-OH MA as a potential toxicity marker. When taken, Fuzi can be broken down by the body into various metabolites. The enzymes responsible for this process are crucial in determining the compound's toxicity.

The breakdown of 10-OH MA involves several enzymes, primarily CYP3A5 and CYP3A4. These enzymes help convert 10-OH MA into less toxic compounds. In human and mouse liver microsomes, 10-OH MA is transformed into multiple metabolites through processes like hydroxylation, dehydrogenation, and demethylation. When CYP3A5 and CYP3A4 are inhibited, the body's ability to break down 10-OH MA is impaired. This impairment leads to increased levels of 10-OH MA in the plasma and tissues.

In mice, inhibiting CYP3A enzymes resulted in a significant increase in 10-OH MA concentrations. This increase was accompanied by enhanced cardiotoxicity and neurotoxicity. The LD50 value, which indicates the lethal dose required to kill 50% of test subjects, decreased sharply. This means that even lower doses of 10-OH MA became more toxic when CYP3A enzymes were inhibited. Other compounds, like diltiazem, can also affect 10-OH MA levels by inhibiting CYP3A enzymes.

The interaction between 10-OH MA and CYP3A enzymes is complex. Not only does 10-OH MA rely on these enzymes for breakdown, but it also competes with them for binding sites. This competitive inhibition can lead to increased toxicity risks when 10-OH MA is taken with other substances that inhibit CYP3A. The risks associated with coexposure to 10-OH MA and CYP3A inhibitors highlight the need for careful consideration when administering Fuzi alongside other medications.

Understanding the role of CYP3A5 and CYP3A4 in 10-OH MA metabolism and toxicity can help predict potential risks. By recognizing the impact of CYP3A inhibition on 10-OH MA levels and toxicity, healthcare professionals can take steps to minimize adverse effects. This knowledge can contribute to safer use of Fuzi and related compounds in traditional medicine.